SCHEMBL3383070

SCHEMBL3383070

CCOC(=O)C(C(C)=O)C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
HSD17B10 Q99714 2/20 0.42
LMNA P02545 2/20 0.42
ALOX15 P16050 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
SOAT1 P35610 1/20 0.36
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CAD P27708 1/20 0.34
PKM P14618 2/20 0.33
KDM4E B2RXH2 1/20 0.33
TRPA1 O75762 1/20 0.33
GLO1 Q04760 1/20 0.33
HDAC4 P56524 2/20 0.33
HDAC6 Q9UBN7 2/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20473345 0.89 ALDH1A1 (0.43) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL14999139 0.82 ALDH1A1 (0.38) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL22912542 0.81 ALDH1A1 (0.37) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL4149915 0.80 ALDH1A1 (0.44) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL28169817 0.79 ALDH1A1 (0.36) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL6209988 0.79 HSD17B10 (0.37) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL15567887 0.79 ALDH1A1 (0.36) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL18643739 0.77 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2
SCHEMBL28169163 0.77
SCHEMBL27776294 0.77 ALDH1A1 (0.41) ALDH1A1HSD17B10LMNAALOX15MGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060100430-A1 Process for preparation of 2-alkoxy-6-(trifluoromethyl)pyrimidin-4-ol LONZA AG (CH) 2006-05-11 US claimed
EP-1592672-A2 PROCESS FOR PREPARATION OF 2-ALKOXY-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-OL Lonza Ltd (CH) 2005-11-09 EP claimed
WO-2004066905-A3 PROCESS FOR PREPARATION OF 2-ALKOXY-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-OL LONZA AG (CH) 2005-01-20 WO claimed
WO-2004066905-A2 PROCESS FOR PREPARATION OF 2-ALKOXY-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-OL LONZA LTD (CH) 2004-08-12 WO claimed
CN-1200717-A Process for preparing 4-bromo-1,1-difluorbut-1-ene and 2,4-dibromo-1,1,1-trifluorobutane ZENECA LTD (GB) 1998-12-02 CN claimed
EP-0850211-A1 PROCESS FOR THE PREPARATION OF 4-BROMO-1,1-DIFLUOROBUT-1-ENE AND 2,4-DIBROMO-1,1,1-TRIFLUOROBUTANE ZENECA LIMITED (GB) 1998-07-01 EP claimed
WO-1997009292-A1 PROCESS FOR THE PREPARATION OF 4-BROMO-1,1-DIFLUOROBUT-1-ENE AND 2,4-DIBROMO-1,1,1-TRIFLUOROBUTANE ZENECA LIMITED (GB) 1997-03-13 WO claimed
WO-2024178967-A1 NON-CHEMICALLY AMPLIFIED COUMARIN PHOTORESISTS SUITABLE FOR PERFORMING PHOTOETCHING AT VARIOUS WAVELENGTHS, AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国科学院理化技术研究所 2024-09-06 WO disclosed
US-11702396-B2 Hydrophobic compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-07-18 US disclosed
EP-4021441-A1 MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF Trustees of Dartmouth College (US) 2022-07-06 EP disclosed
WO-2021042046-A1 MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF TRUSTEES OF DARTMOUTH COLLEGE (US) 2021-03-04 WO disclosed
CN-110437146-A A kind of preparation of quinoline 4- hydroxy methacrylates class compound and its application in controlling plant diseases UNIV LANZHOU 2019-11-12 CN disclosed
CN-104829605-B 1 substitution 5 trifluoromethyl 4 pyrazoles joins 1,3,4 oxadiazole thioethers or sulfone derivatives and its application 贵州大学 2018-03-23 CN disclosed
US-5693646-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-02 US disclosed
US-5693647-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-02 US disclosed
US-5688808-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-11-18 US disclosed
US-5688810-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-11-18 US disclosed
EP-0800519-A1 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 1997-10-15 EP disclosed
WO-1997009292-A1 PROCESS FOR THE PREPARATION OF 4-BROMO-1,1-DIFLUOROBUT-1-ENE AND 2,4-DIBROMO-1,1,1-TRIFLUOROBUTANE ZENECA LIMITED (GB) 1997-03-13 WO disclosed
WO-1996019458-A2 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INCORPORATED (US) 1996-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702396-B2 Hydrophobic compounds for optically active devices UACA, CRYZ, TRPA1 ALDH1A1 1851/4885HSD17B10 647/4885LMNA 2186/4885
US-20060100430-A1 Process for preparation of 2-alkoxy-6-(trifluoromethyl)pyrimidin-4-ol CLCN2, CLIC1, CLIC4 ALDH1A1 436/4885HSD17B10 2841/4885LMNA 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.